📈 In a Phase I trial, weekly injections of CT-388 led to a median weight loss of 18.8% compared to placebo.
💊 CT-388 is a GLP-1/GIP agonist that targets two receptors in the body involved in controlling food intake and energy absorption.
🩺 The results show promise for the treatment of obesity and related comorbidities such as type 2 diabetes and cardiovascular diseases.
Introduction:
Roche has released the first clinical data for its obesity candidate CT-388, following its acquisition of Carmot Therapeutics. CT-388 is a GLP-1/GIP agonist that was added to Roche’s pipeline through the acquisition. The results of the Phase I trial showed that CT-388 led to significant weight loss in patients, with a median weight loss of 18.8% compared to placebo. The drug also normalized blood glucose levels in prediabetic patients. The potential for GLP-1/GIP agonists to treat obesity is significant, as the condition affects over one billion patients worldwide and is associated with numerous comorbidities.
- Roche has released the first clinical data for its obesity candidate CT-388, which was added to the pipeline through its acquisition of Carmot Therapeutics.
- In a Phase I trial, CT-388 led to a median weight loss of 18.8% compared to placebo.
- All patients treated with CT-388 lost more than 5% of their weight, and 70% achieved more than 15% weight loss.
- In addition to weight loss, CT-388 also normalized blood glucose levels in prediabetic patients.
- Obesity is a major global health challenge, with potential life-threatening comorbidities, and GLP-1/GIP agonists like CT-388 have the potential to provide significant benefits in treating the condition.
Conclusion:
The results of the Phase I trial for CT-388, a GLP-1/GIP agonist for obesity, show promising results in terms of weight loss and normalization of blood glucose levels. This is significant as obesity is a significant health challenge globally, and effective treatments are urgently needed. The potential of CT-388 and other GLP-1/GIP agonists to provide meaningful weight loss and improve glucose control offers hope for patients with obesity and its associated comorbidities. Further research and development of these drugs are needed to fully understand their mechanism of action and long-term effects, but the initial data is promising.
